Health Care • Medical Specialities
$33.51 ▼ -1.21
(-3.48%)
MKT CAP: $97.0M • VOL: 1.9K
52W L $32 52W H $43
KEQU // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2026-04-30 | FY 2024
FILED 2025-04-30 | FY 2023
FILED 2024-04-30 |
|---|---|---|---|
| Revenue (Total Sales) | $282.0M | $240.5M | $203.8M |
| YoY Revenue Growth % | +17.3% | +18.0% | — |
| Gross Profit | $80.4M | $68.9M | — |
| Gross Margin % | 28.5% | 28.6% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $16.7M | $17.8M | $18.3M |
| Operating Margin % | 5.9% | 7.4% | 9.0% |
| Net Income (GAAP) | $9.6M | $11.4M | $18.8M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $18.6M | $14.8M | $19.6M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | $18.6M | $14.8M | $19.6M |
| FCF Margin % | 6.6% | 6.1% | 9.6% |
| Return on Invested Capital (ROIC %) | 16.7% | 16.3% | — |
| Cash & Short-Term Equivalents | $8.2M | $9.5M | — |
| Total Debt (Short + Long Term) | $16.3M | $35.0M | — |
| Total Stockholders' Equity | $70.7M | $60.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR KEQU.